Microbial CMO Wacker buys Dutch biotech plant

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Arindam Ghosh)
(Image: Getty/Arindam Ghosh)
Wacker Chemie has acquired SynCo Bio’s site for manufacturing biopharmaceuticals, live microbial products, and vaccines, as well as its associated business, including more than 100 employees.

SynCo Bio Luxembourg S.à.r.l operates two fermentation lines – for the manufacture of microbial-derived biopharmaceuticals for clinical testing and the commercial market – with capacities of 1,500 and 270 L.

According to the Munich-based contract manufacturing organization (CMO) Wacker, the Dutch site also features a line of single-use fermenters and a fill/finish facility, which meet good manufacturing practice (GMP) quality standards and European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval.

This strategic acquisition is a key step for our ongoing expansion in the high-growth biopharmaceuticals market,”​ explained Auguste Willems of Wacker’s executive board.

“The new plant will enable us to satisfy robust market demand today and in the coming years – and to strengthen our position as a leading contract manufacturer of microbial-derived biopharmaceutical proteins,” ​he said in the press release.

Wacker is a contract manufacturer of biopharmaceutical proteins based on microbial systems. The company provides analytical services and process development for the manufacture of clinical test samples and pharmaceutical actives for the commercial market.

Under the agreement – terms of which were not disclosed – Wacker will retain all 110 SynCo employees.

Wacker is not providing any additional comment at this time.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us


View more